Prevalência de sintomas persistentes em indivíduos infectados pelo novo coronavírus após 30 dias de diagnóstico
Palavras-chave:
Infecção pelo Coronavírus, COVID-19, Avaliação de sintomas
Resumo
Após infecção aguda pelo SARS-CoV 2 os pacientes podem apresentar sintomas persistentes e heterogêneos que afetam órgãos e sistemas. O objetivo foi analisar a persistência de sintomas da COVID-19 após 30 dias do diagnóstico. Estudo transversal incluindo adultos maiores de 18 anos, ambos os sexos, com diagnóstico de COVID-19 em Londrina-PR. A coleta de dados foi por meio de questionário (WhatsApp) abordando aspectos demográficos, estado funcional e sintomas. Foram avaliados 1.021 indivíduos com mediana de idade de 34 [26-44] anos, boa escolaridade, 36,4% tinham comorbidades, e poucos necessitaram de internação. Apresentaram limitação funcional 56,3% dos pacientes e, após um mês, 57,2% apresentavam fadiga e 34,8% dispneia. Mulheres tiveram significativamente mais fadiga 61,7%, dispneia 38,8% e maior limitação funcional 65,3%. Homens tiveram mais internação e maior relato de sintomas. Concluiu-se que 73,5% dos participantes relataram permanência de ao menos um sintoma após 30 dias e os mais prevalentes foram fadiga, anosmia e cefaleia.
Referências
1. Gulati A, Pomeranz C, Qamar Z, Thomas S, Frisch D, George G, et al. A Comprehensive Review of Manifestations of Novel Coronaviruses in the Context of Deadly COVID-19 Global Pandemic. Am J Med Sci. 2020;360(1):5-34. [acessado 12 jan 2021]. doi: https://doi.org/10.1016/j.amjms.2020.05.006
2. Macedo YM, Ornellas JL, Bomfim HF do. COVID – 19 NO BRASIL: o que se espera para população subalternizada? Encantar [Internet]. 2020 [citado 18 nov 2021];20:01-10. [acessado 12 Jan 2021]. Disponível em: https://revistas.uneb.br/index.php/encantar/article/view/8189.
3. Souza CDF, Paiva JPS, Leal TC, Silva LF, Santos LG. Evolução espaço temporal da letalidade por COVID-19 no Brasil, 2020 [carta ao editor]. J Bras Pneumol. 2020;46(4):e20200208. [acessado 07 Jan 2021]. doi: https://doi.org/10.36416/1806-3756/e20200208.
4. Coronavirus disease (COVID-19) situation reports [Internet]. [citado 18 nov 2021]. Disponível em: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
5. Brasil. Ministério da Saúde - Painel Coronavírus. [acessado 15 nov 2021]. Disponível em: https://covid.saude.gov.br.
6. Paraná. Secretaria de Saúde do Estado SESA. [acessado 15 nov 2021]. Disponível em: https://www.saude.pr.gov.br/Pagina/Coronavirus-COVID-19.
7. Autarquia Municipal de Saúde de Londrina. [acessado 15 nov 2021]. Disponível em: https://saude.londrina.pr.gov.br/index.php/dados-epidemiologicos/informe-epidemiologico.html.
8. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324(8):782-93. [acessado 28 jan 2021]. doi: https://doi.org/10.1001/jama.2020.12839.
9. World Health Organization (WHO). Origin of SARS-CoV-2, 26 March 2020. World Health Organization, 2020. [acessado 22 fev 2021]. Disponível em: https://apps.who.int/iris/bitstream/handle/10665/332197/WHO-2019-nCoV-FAQ-Virus_origin-2020.1-eng.pdf.
10. Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al. Persistent symptoms after Covid-19: qualitative study of 114 “long Covid” patients and draft quality principles for services. BMC Health Serv Res. 2020;20(1):1-13. [acessado 22 fev 2021]. doi: https://doi.org/10.1186/s12913-020-06001-y.
11. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–15. [acessado 02 fev 2021]. doi: https://doi.org/10.1038/s41591-021-01283-z.
12. Wong AW, Shah AS, Johnston JC, Carsten C, Ryerson CJ. Patient-reported outcome measures after COVID-19: a prospective cohort study. Eur Respir J. 2020;56(5):2003276. [acessado 14 fev 2021]. doi: https://doi.org/10.1183/13993003.03276-2020
13. Klok FA, Boon GJAM, Barco S, Endres M, Geelhoed JJM, Knauss S, et al. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. Eur Respir J. 2020;56(1):2001494. [acessado em 24 Jan 2021]. doi: https://doi.org/10.1183/13993003.01494-2020.
14. Machado FVC, Meys R, Delbressine JM, Vaes AW, Goërtz YMJ, van Herck M, et al. Construct validity of the Post-COVID-19 Functional Status Scale in adult subjects with COVID-19. Health Qual Life Outcomes. 2021;19(1):1-10. [acessado 12 fev 2021]. doi: https://doi.org/10.1186/s12955-021-01691-2.
15. Krupp LB, Larocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiples esclerosis and systemic lupus erythematosus. Arch Neurol. 1989,46(10):1121-3. [acessado 07 Fev 2021]. doi: https://doi.org/10.1001/archneur.1989.00520460115022.
16. Alvarenga Filho H, Carvalho SRS, Dias RM, Alvarenga RMP. Principais testes utilizados na avaliação de fadiga na esclerose múltipla: revisão sistemática. Rev Bras Neurol. 2010;46(2):37-43. [acessado 07 Fev 2021]. Disponível em: http://files.bvs.br/upload/S/0101-8469/2010/v46n2/a0006.pdf.
17. Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435-52. [acessado 07 fev 2021]. doi: https://doi.org/10.1164/rccm.201111-2042ST.
18. World Health Organization. Support for rehabilitation: self-management after COVID-19 related illness. No. WHO/EURO: 2021-855-40590-59892. World Health Organization. Regional Office for Europe, 2021. [acessado 15 nov 2021]. Disponível em: https://cdn.who.int/media/docs/default-source/ageing/support-for-rehabilitation-self-management-after-covid-19-related-illness-engf5cec00b-350b-4eb0-bc24-0704df509ae1.pdf?sfvrsn=203566f0_1&download=true.
19. Mukaka MM. Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24(3):69-71. [acessado 17 jan 2021]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/23638278/
20. Pavli A, Theodoridou M, Maltezou HC. Post-COVID Syndrome: Incidence, Clinical Spectrum, and Challenges for Primary Healthcare Professionals. Arch Med Res. 2021;52(6):575-81. [acessado 16 nov 2021]. doi: https://doi.org/10.1016/j.arcmed.2021.03.010.
21. Rezer F, Faustino WR, Maia CS. Taxas de COVID-19 nas mesorregiões de Mato Grosso: casos confirmados e notificados. Rev Pre Infec e Saúde. [Internet] 2020;6:10317. [acessado 07 fev 2021]. Disponível em: https://revistas.ufpi.br/index.php/nupcis/article/download/10317/pdf
22. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med. 2020;26382(13):1199-207. [acessado 07 fev 2021]. doi: https://doi.org/10.1056/NEJMoa2001316.
23. Han Y, Liu Y, Zhou L, Chen E, Liu P, Pan X, et al. Epidemiological Assessment of Imported Coronavirus Disease 2019 (COVID-19) Cases in the Most Affected City Outside of Hubei Province, Wenzhou, China. JAMA Netw Open. 2020;3(4):e206785. [acessado 07 fev 2021]. doi: https://doi.org/10.1001/jamanetworkopen.2020.6785.
24. Outhoff K. Sick and tired of COVID-19: long haulers and post viral (fatigue) syndromes [editorial]. South Afr Gen Pract J. 2020;1(4):132-3. [acessado 07 fev 2021]. doi: https://doi.org/10.36303/SAGP.2020.1.4.0041.
25. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. [acessado 07 fev 2021]. doi: https://doi.org/10.1016/S0140-6736(20)30183-5.
26. Hasan ATMH, Islam MS, Khan N, Munna NH, Choton WR, Arefin MK, et al. Assessment of Post SARS CoV 2 Fatigue among Physicians Working in COVID Designated Hospitals in Dhaka, Bangladesh. medRxiv. 2021. [acessado 07 fev 2021]. doi: https://doi.org/10.1101/2021.02.08.21251352
27. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y, et al. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact. medRxiv. 2020. [acessado 07 fev 2021]. doi: https://doi.org/10.1101/2020.12.24.20248802.
28. Bolay H, Gül A, Baykan B. COVID‐19 is a Real Headache! Headache.. 2020;60(7):1415–21. [acessado 14 fev 2021]. doi: https://doi.org/10.1111/head.13856
29. Weng LM, Su X, Wang XQ. Pain Symptoms in Patients with Coronavirus Disease (COVID-19): A Literature Review. J Pain Res. 2021;14:147-59. [acessado 14 fev 2021]. doi:https://doi.org/10.2147/JPR.S269206.
30. Mohamed-Hussein A, Galal I, Saad M, Zayan HE, Abdelsayed M, Moustafa M, et al. Post-COVID-19 Functional Status: Relation to age, smoking, hospitalization and comorbidities. medRxiv. 2020. [acessado 14 fev 2021]. doi: https://doi.org/10.1101/2020.08.26.20182618.
2. Macedo YM, Ornellas JL, Bomfim HF do. COVID – 19 NO BRASIL: o que se espera para população subalternizada? Encantar [Internet]. 2020 [citado 18 nov 2021];20:01-10. [acessado 12 Jan 2021]. Disponível em: https://revistas.uneb.br/index.php/encantar/article/view/8189.
3. Souza CDF, Paiva JPS, Leal TC, Silva LF, Santos LG. Evolução espaço temporal da letalidade por COVID-19 no Brasil, 2020 [carta ao editor]. J Bras Pneumol. 2020;46(4):e20200208. [acessado 07 Jan 2021]. doi: https://doi.org/10.36416/1806-3756/e20200208.
4. Coronavirus disease (COVID-19) situation reports [Internet]. [citado 18 nov 2021]. Disponível em: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
5. Brasil. Ministério da Saúde - Painel Coronavírus. [acessado 15 nov 2021]. Disponível em: https://covid.saude.gov.br.
6. Paraná. Secretaria de Saúde do Estado SESA. [acessado 15 nov 2021]. Disponível em: https://www.saude.pr.gov.br/Pagina/Coronavirus-COVID-19.
7. Autarquia Municipal de Saúde de Londrina. [acessado 15 nov 2021]. Disponível em: https://saude.londrina.pr.gov.br/index.php/dados-epidemiologicos/informe-epidemiologico.html.
8. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324(8):782-93. [acessado 28 jan 2021]. doi: https://doi.org/10.1001/jama.2020.12839.
9. World Health Organization (WHO). Origin of SARS-CoV-2, 26 March 2020. World Health Organization, 2020. [acessado 22 fev 2021]. Disponível em: https://apps.who.int/iris/bitstream/handle/10665/332197/WHO-2019-nCoV-FAQ-Virus_origin-2020.1-eng.pdf.
10. Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al. Persistent symptoms after Covid-19: qualitative study of 114 “long Covid” patients and draft quality principles for services. BMC Health Serv Res. 2020;20(1):1-13. [acessado 22 fev 2021]. doi: https://doi.org/10.1186/s12913-020-06001-y.
11. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–15. [acessado 02 fev 2021]. doi: https://doi.org/10.1038/s41591-021-01283-z.
12. Wong AW, Shah AS, Johnston JC, Carsten C, Ryerson CJ. Patient-reported outcome measures after COVID-19: a prospective cohort study. Eur Respir J. 2020;56(5):2003276. [acessado 14 fev 2021]. doi: https://doi.org/10.1183/13993003.03276-2020
13. Klok FA, Boon GJAM, Barco S, Endres M, Geelhoed JJM, Knauss S, et al. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. Eur Respir J. 2020;56(1):2001494. [acessado em 24 Jan 2021]. doi: https://doi.org/10.1183/13993003.01494-2020.
14. Machado FVC, Meys R, Delbressine JM, Vaes AW, Goërtz YMJ, van Herck M, et al. Construct validity of the Post-COVID-19 Functional Status Scale in adult subjects with COVID-19. Health Qual Life Outcomes. 2021;19(1):1-10. [acessado 12 fev 2021]. doi: https://doi.org/10.1186/s12955-021-01691-2.
15. Krupp LB, Larocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiples esclerosis and systemic lupus erythematosus. Arch Neurol. 1989,46(10):1121-3. [acessado 07 Fev 2021]. doi: https://doi.org/10.1001/archneur.1989.00520460115022.
16. Alvarenga Filho H, Carvalho SRS, Dias RM, Alvarenga RMP. Principais testes utilizados na avaliação de fadiga na esclerose múltipla: revisão sistemática. Rev Bras Neurol. 2010;46(2):37-43. [acessado 07 Fev 2021]. Disponível em: http://files.bvs.br/upload/S/0101-8469/2010/v46n2/a0006.pdf.
17. Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435-52. [acessado 07 fev 2021]. doi: https://doi.org/10.1164/rccm.201111-2042ST.
18. World Health Organization. Support for rehabilitation: self-management after COVID-19 related illness. No. WHO/EURO: 2021-855-40590-59892. World Health Organization. Regional Office for Europe, 2021. [acessado 15 nov 2021]. Disponível em: https://cdn.who.int/media/docs/default-source/ageing/support-for-rehabilitation-self-management-after-covid-19-related-illness-engf5cec00b-350b-4eb0-bc24-0704df509ae1.pdf?sfvrsn=203566f0_1&download=true.
19. Mukaka MM. Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24(3):69-71. [acessado 17 jan 2021]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/23638278/
20. Pavli A, Theodoridou M, Maltezou HC. Post-COVID Syndrome: Incidence, Clinical Spectrum, and Challenges for Primary Healthcare Professionals. Arch Med Res. 2021;52(6):575-81. [acessado 16 nov 2021]. doi: https://doi.org/10.1016/j.arcmed.2021.03.010.
21. Rezer F, Faustino WR, Maia CS. Taxas de COVID-19 nas mesorregiões de Mato Grosso: casos confirmados e notificados. Rev Pre Infec e Saúde. [Internet] 2020;6:10317. [acessado 07 fev 2021]. Disponível em: https://revistas.ufpi.br/index.php/nupcis/article/download/10317/pdf
22. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med. 2020;26382(13):1199-207. [acessado 07 fev 2021]. doi: https://doi.org/10.1056/NEJMoa2001316.
23. Han Y, Liu Y, Zhou L, Chen E, Liu P, Pan X, et al. Epidemiological Assessment of Imported Coronavirus Disease 2019 (COVID-19) Cases in the Most Affected City Outside of Hubei Province, Wenzhou, China. JAMA Netw Open. 2020;3(4):e206785. [acessado 07 fev 2021]. doi: https://doi.org/10.1001/jamanetworkopen.2020.6785.
24. Outhoff K. Sick and tired of COVID-19: long haulers and post viral (fatigue) syndromes [editorial]. South Afr Gen Pract J. 2020;1(4):132-3. [acessado 07 fev 2021]. doi: https://doi.org/10.36303/SAGP.2020.1.4.0041.
25. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. [acessado 07 fev 2021]. doi: https://doi.org/10.1016/S0140-6736(20)30183-5.
26. Hasan ATMH, Islam MS, Khan N, Munna NH, Choton WR, Arefin MK, et al. Assessment of Post SARS CoV 2 Fatigue among Physicians Working in COVID Designated Hospitals in Dhaka, Bangladesh. medRxiv. 2021. [acessado 07 fev 2021]. doi: https://doi.org/10.1101/2021.02.08.21251352
27. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y, et al. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact. medRxiv. 2020. [acessado 07 fev 2021]. doi: https://doi.org/10.1101/2020.12.24.20248802.
28. Bolay H, Gül A, Baykan B. COVID‐19 is a Real Headache! Headache.. 2020;60(7):1415–21. [acessado 14 fev 2021]. doi: https://doi.org/10.1111/head.13856
29. Weng LM, Su X, Wang XQ. Pain Symptoms in Patients with Coronavirus Disease (COVID-19): A Literature Review. J Pain Res. 2021;14:147-59. [acessado 14 fev 2021]. doi:https://doi.org/10.2147/JPR.S269206.
30. Mohamed-Hussein A, Galal I, Saad M, Zayan HE, Abdelsayed M, Moustafa M, et al. Post-COVID-19 Functional Status: Relation to age, smoking, hospitalization and comorbidities. medRxiv. 2020. [acessado 14 fev 2021]. doi: https://doi.org/10.1101/2020.08.26.20182618.
Publicado
2021-12-23
Como Citar
1.
Fillis MMA, Laskovski L, Felcar JM, Trelha CS. Prevalência de sintomas persistentes em indivíduos infectados pelo novo coronavírus após 30 dias de diagnóstico. Revista de Saúde Pública do Paraná [Internet]. 23dez.2021 [citado 22nov.2024];4(4):44-0. Available from: http://revista.escoladesaude.pr.gov.br/index.php/rspp/article/view/561
Edição
Seção
Artigos originais
This work is licensed under a Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
A) Autores mantêm os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
B) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
C) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal).
